Clinical Trials Logo

Intestinal Inflammation clinical trials

View clinical trials related to Intestinal Inflammation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06396728 Not yet recruiting - Gut Microbiota Clinical Trials

Use of GI BIOTICS 100B UFC to Improve Intestinal Health in Older Adults

GIBIOTICS
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Type of study: Clinical Trial. Main objective: To study the effect of daily consumption of the probiotic (GI BIOTICS 100B UFC) on intestinal inflammatory markers, intestinal microbiota, intestinal health, body composition and sports performance in older adults for 8 weeks. Participant Population/Health Conditions: The study will involve 44 sedentary men with a body mass index > 25 kg/m2 and aged between 60 and 75 years. Participants Will: Be randomised into one of two groups: consumption of a placebo capsule (comparison group) and consumption of GI BIOTICS 100B UFC daily for a period of 8 weeks (experimental group). Provide feces and blood samples before and after the 8-week intervention. Undergo analysis of these samples using advanced techniques to understand the effect of the consumption of the probiotic. Undergo a submaximal stress test and muscle strength will be measured using a handgrip dynamometer.

NCT ID: NCT06149949 Not yet recruiting - Rhinosinusitis Clinical Trials

the Prevalence of Chronic Rhinosinusitis Associated With Inflammatory Bowel Disease and Association With Biomarkers of Epithelial Barrier Damage

PRIME
Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to define the prevalence of chronic rhinosinusitis in patients with intestinal bowel disease. The main questions it aims to answer are: - Evaluate the influence of chronic rhinosinusitis on the quality of life of patients with intestinal bowel disease - Evaluate any relationships between chronic rhinosinusitis and the clinical course of intestinal bowel disease -Evaluate the influence of chronic rhinosinusitis on the response to biologic therapies for intestinal bowel disease - Evaluate mucosal barrier damage in patients with chronic rhinosinusitis and intestinal bowel disease by collecting blood and stool samples according to clinical practice - Presence of enterotoxin sensitization to S. Aureus in patients with intestinal bowel disease - Histopathological evaluation: reevaluation of biopsy slides performed according to clinical practice will be performed in patients with chronic rhinosinusitis and intestinal bowel disease in order to quantify the proportion of eosinophilic infiltrate at the intestinal level and to assess any differences from the population with intestinal bowel disease only. Patients with intestinal bowel disease afferent to our outpatient chronic inflammatory bowel disease clinic at CEMAD will be enrolled.